Congestive Heart Failure and Virchow's Triad: A Neglected Association

Wiener Medizinische Wochenschrift

Volumn 153, Issue 19-20, 2003, Pages 411-416

  Sosin, Michael D ^a   Bhatia, Gurbir ^a   Davis, Russell C ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Antiplatelet agents; Congestive heart failure; Coumarins; Stroke; Thromboembolism; Venous; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; MELAGATRAN; RAMIPRIL; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLOOD RHEOLOGY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; HEART ARRHYTHMIA; HEART DILATATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; REVIEW; STROKE; SUDDEN DEATH; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ANTICOAGULANTS; CARDIAC OUTPUT; DEATH, SUDDEN, CARDIAC; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; INTRACRANIAL EMBOLISM; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; VENOUS THROMBOSIS;

EID: 0242637082     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-003-0027-y     Document Type: Review

References (66)

1. Ackman ML, Harjee KS, Mansell G, Campbell JB, Teo KK, Montague TJ: Cause-specific non-cardiac mortality in patients with congestive heart failure - a contemporary Canadian audit. Clinical Quality Improvement (CQIN) Investigators. Can J Cardiol 1996;12: 809-813.
2. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA: Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1992;20:1549-1555.
3. Anderson GM, Hull E: The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 1950;39:697-702.
4. Anderson TJ, Elstein E, Haber H, Charbonneau F: Comparative Study of ACE-Inhibition, Angiotensin II antagonism, and Calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-66.
5. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994;154:1449-1457.
6. Blann AD, Lip GYH, Islim IF, Beevers DG: Platelet activation in hypertension. J Hum Hypertens 1997;11:607-609.
7. Bowker TJ, Wood DA, Davies MJ: Sudden unexpected cardiac death: methods and results of a national pilot survey. Int J Cardiol 1995;52:241-250.
8. Broderisk JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP: Relationship of cardiac disease to stroke occurrence, recurrence and mortality. Stroke 1992;23:1250-1256.
9. Buxton A, Lee K, Fisher J, Josephson M, Prystowsky E, Hafley M: A randomized study of the prevention of sudden cardiac death in patients with coronary artery disease. N Engl J Med 1999;341: 1882-1890.
10. Cabin HS, Roberts WC, Ferrans VJ: Left ventricular aneurysm, intra-aneurysmal thrombus, and systemic embolus in coronary heart disease. Chest 1980;77:586-590.
11. Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F, Tavazzi L: Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996;17:1381-1389.
12. Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG: Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J 1997;18;41-51.
13. Cleland JGF, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Rydén L: Cardiovascular critical event pathways for the progression of heart failure - a report from the ATLAS study. Eur Heart J 2001;22:1601-1612.
14. Cregler LL: Antithrombotic therapy in left ventricular thrombosis and systemic embolism. Am Heart J 1991;123:1110-1114.
15. Cupples LA, Gagnon DR, Kannel WB: Long-and short-term risk of sudden coronary death. Circulation 1992;85[Suppl I]:I11-I18.
16. Davies MJ: Anatomic features in victims of sudden cardiac death. Circulation 1992;85[Suppl I]:119-124.
17. Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
18. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ: Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997;79:909-913.
19. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ: Ejection fraction and risk of Thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence for gender differences in the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1997;29:1074-1080.
20. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN: Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87[Suppl VI]:VI94-VI101.
21. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-1447.
22. Falk RH, Foster E, Coats MH: Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective follow-up study. Am Heart J 1992;123:136-142.
23. Falk RH, Pollak A, Tandon PK, Packer M for the PROMISE investigators: The effect of warfarin on the prevalence of stroke in patients with severe heart failure. Abstract. J Am Coll Cardiol 1993;21:218A.
24. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL: The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-531.
25. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-1456.
26. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB: Prevention of venous thromboembolism. Chest 2001;119:132S-75S.
27. Gibbs CR, Blann AD, Watson RD, Lip GY: Abnormalities of haemorheological, endothelial and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and β-blocker therapy. Circulation 2001;103:1746-1451.
28. Griffith GC, Stragnell R, Levinson DC, Moore FJ, Ware AG: A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952;37:867-887.
29. Harvey WP, Finch CA: Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950;242: 208-211.
30. Hendra TJ, Oswald GA, Yudkin JS: Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Res Clin Pract 1988;59:259-263.
31. Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK: Impact of heart failure and left ventricular systolic dysfunction on quality of life. Eur Heart J 2002;23:1867-1876.
32. Jansson JH, Nilsson TK, Johnson O: Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-355.
33. Katz SD, Marantz PR, Biascucci L, Jondeau G, Lee K, Brenan C, LeJemtel TH: Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993;126:141-146.
34. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM: Endothelium-dependent vasodilatation is attenuated in patients with heart failure. Circulation 1991;84:1589-1596.
35. Kyrle PA, Korninger C, Gossinger H, Glogar D, Lechner K, Niessner H, Pabinger I: Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost 1985;54:521-523.
36. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK: The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
37. Lip GYH, Blann AD: Von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995;580-583.
38. Lip GYH, Gibbs CR: Anticoagulation for heart failure in sinus rhythm (Cochrane Review). In: The Cochrane Library, Issue 4, 2001. Update Software, Oxford.
39. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA: Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:310-313.
40. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B: Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study. Circulation 1996;94:258-265.
41. Maze SS, Kotler MN, Parry WR: Flow characteristics in the dilated left ventricle with thrombus. J Am Coll Cardiol 1989;13:873-881.
42. Mehta J, Mehta P: Platelet function studies in heart disease: enhanced platelet aggregate formation in congestive heart failure. Circulation 1979;60:497-503.
43. Meltzer RS, Visser CA, Fuster V: Intracardiac thrombi and systemic embolism. Ann Intern Med 1986;104:689-698.
44. Middlekauf HR, Stevenson WG, Stevenson LW: Prognostic significance of atrial fibrillation in advanced heart failure. J Am Coll Cardiol 1993;12:14A-19A.
45. Mohiaddin RH: Flow patterns in the dilated ischaemic left ventricle studied by MR imaging with velocity vector mapping. J Magn Reson Imaging 1995;5:493-498.
46. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M: Improved survival with an implantable defibrillator in patients with coronary disease at high risk for malignant ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.
47. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW: Risk of arterial embolisation in 224 patients awaiting cardiac transplantation. Am Heart J 1995;129:564-570.
48. O'Connor CM, Gurbel PA, Serebruany VL: Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-1349.
49. Packer M: Lack of relation between ventricular arrythmias and sudden death in patients with chronic heart failure. Circulation 1992;85[Suppl I]:I50-I56.
50. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Anderson B: Placebo-controlled, randomised trial of warfarin and aspirin for the prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-179.
51. Pullicino PM, Thompson JL, Martinez AL, Graham S, Barton B, Chan R, Levin B: Warfarin vs Aspirin Reduced Cardiac Ejection Fraction Study (WARCEF) Ongoing Clinical Trials Session, 27th International Stroke Conference, San Antonio, Texas, 2002.
52. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG: Relationship between haemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127: 607-612.
53. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
54. Stratton JR, Resnick AD: Increased embolic risk in patients with left ventricular thrombi. Circulation 1997;75:1004-1011.
55. Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992;116(1):1-5.
56. Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116(1):6-12.
57. Sutton GC: Epidemiological aspects of heart failure. Am Heart J 1990;120:1538-1540.
58. Swedberg K for the CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
59. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R; ACE Inhibitors Collaborative Group: Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-1043.
60. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341: 857-865.
61. Turpie AG: Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000;86:48M-52M.
62. Uretsky B, Armstrong PW, Cleland JGF: Ischaemia as a trigger for sudden death in patients with cardiomyopathy and heart failure secondary to coronary artery disease: results from the ATLAS trial (Abstract). Circulation 1998;98[Suppl I]:I199.
63. Verma S, Anderson TJ: Fundamentals of Endothelial function for the clinical cardiologist. Circulation 2002;105:546-549.
64. Virchow R: Gesammalte abhandlungen zur wissenschaftlichen medtzin. Medinger Sohn & Co., Frankfurt, 1856; pp 219-732.
65. Weinreich DJ, Burke JF, Pauletto FJ: Left Ventricular mural thrombi complicating acute myocardial infarction: long term follow-up with serial echocardiography. Ann Intern Med 1984;100:789-794.
66. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.